{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:12:18Z","timestamp":1710342738165},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7539","type":"journal-article","created":{"date-parts":[[2017,1,14]],"date-time":"2017-01-14T22:10:54Z","timestamp":1484431854000},"page":"191-196","source":"Crossref","is-referenced-by-count":6,"title":["Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome"],"prefix":"10.2169","volume":"56","author":[{"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[{"name":"Deaprtment of Cardiovascular Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Pathology, Koshigaya Hospital, Dokkyo University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[{"name":"Deaprtment of Cardiovascular Medicine, Saga University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Imamura T, Kinugawa K, Fujino T, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 78: 2240-2249, 2014.","DOI":"10.1253\/circj.CJ-14-0244"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Imamura T, Kinugawa K. Urine aquaporin-2: a promising marker of response to the arginine vasopressin type-2 antagonist, tolvaptan in patients with congestive heart failure. Int J Mol Sci 17: pii: E105, 2016.","DOI":"10.3390\/ijms17010105"},{"key":"3","unstructured":"3. Yang CJ, Yang J, Yang J, Fan ZX. Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 8: 22117-22128, 2015."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: association between non-responders and chronic kidney disease. Circ J 77: 397-404, 2013.","DOI":"10.1253\/circj.CJ-12-0971"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tanaka A, Katsuno T, Ozaki T, et al. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol 70: 217-223, 2015.","DOI":"10.1080\/AC.70.2.3073514"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Park ES, Huh YS, Kim GH. Is tolvaptan indicated for refractory oedema in nephrotic syndrome? Nephrology 20: 103-106, 2015.","DOI":"10.1111\/nep.12348"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chen M, Cai H, Klein JD, Laur O, Chen G. Dexamethasone increases aquaporin-2 protein expression in <i>ex vivo<\/i> inner medullary collecting duct suspensions. Front Physiol 6: 310, 2015.","DOI":"10.3389\/fphys.2015.00310"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jensen JM, Mose FH, Kulik AE, Bech JN, Fenton RA, Pedersen EB. Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: an intervention study in patients with chronic kidney disease and healthy controls. BMC Nephrol 15: 101, 2014.","DOI":"10.1186\/1471-2369-15-101"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Imamura T. Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease. Int Heart J 55: 482-483, 2014.","DOI":"10.1536\/ihj.14-217"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wang Y, Wang GP, Li BM, Chen QK. Clinicopathological analysis of idiopathic membranous nephropathy in young adults. Genet Mol Res 14: 4541-4548, 2015.","DOI":"10.4238\/2015.May.4.12"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sato E, Nakamura T, Amaha M, et al. Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int Heart J 55: 533-538, 2014.","DOI":"10.1536\/ihj.14-190"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Polanco N, Guti\u00e9rrez E, Covars\u00ed A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010.","DOI":"10.1681\/ASN.2009080861"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Peng L, Wei SY, Li LT, He YX, Li B. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. J Formos Med Assoc 115: 11-18, 2016.","DOI":"10.1016\/j.jfma.2015.07.021"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Iwatani H, Kawabata H, Sakaguchi Y, et al. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron 130: 8-12, 2015.","DOI":"10.1159\/000381859"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tanaka A, Nakamura T, Sato E, et al. Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome. Int J Cardiol 210: 103, 2016.","DOI":"10.1016\/j.ijcard.2016.02.106"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Radin MJ, Yu MJ, Stoedklide L, et al. Aquaporin-2 regulation in health and disease. Vet Clin Pathol 41: 455-470, 2012.","DOI":"10.1111\/j.1939-165x.2012.00488.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/2\/56_56.7539\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T15:23:22Z","timestamp":1568733802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/2\/56_56.7539\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7539","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}